Tin tức & Cập nhật
Xem bài viết Hô hấp
Xem

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.

Nivolumab-chemo poised to alter NSCLC treatment landscape
In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).

First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.





